Human papillomavirus infection

Asia Pacific Travel Vaccines Market Report 2022: Surge in Incidences of Infectious Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022

The Asia Pacific travel vaccines market is expected to grow at a good CAGR during the forecast period.

Key Points: 
  • The Asia Pacific travel vaccines market is expected to grow at a good CAGR during the forecast period.
  • The Asia Pacific travel vaccines market, based on product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others.
  • The Asia Pacific travel vaccines market, based on application, is segmented into domestic travel and outbound travel.
  • Based on country, the Asia Pacific travel vaccines market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific.

Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Thursday, August 25, 2022

We believe this could offer hope for a new immunotherapy treatment option to patients with recurrent/metastatic end-stage cervical cancer.

Key Points: 
  • We believe this could offer hope for a new immunotherapy treatment option to patients with recurrent/metastatic end-stage cervical cancer.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
  • Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics.
  • Genexine has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value.

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Tuesday, August 9, 2022

OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Companys recent corporate developments.

Key Points: 
  • OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Companys recent corporate developments.
  • Second Quarter 2022 Financial Highlights:
    Cash position: As of June 30, 2022, cash and cash equivalents were $192.3 million, compared to $214.1 million as of December 31, 2021.
  • Revenues: Revenues were $17.1 million in the second quarter of 2022 compared to $15.0 million in the first quarter of 2022.
  • Research and development expenses: Research and development expenses were $9.7 million in the second quarter of 2022 compared to $10.7 million in the first quarter of 2022.

Global Human Papillomavirus Vaccine Market Forecast to 2028: Advancements in HPV Diagnostics Tests & Growing Number of HPV Awareness Programs - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022

The global human papillomavirus (HPV) vaccine market was valued at US$ 4,273.84 million in 2022 and is projected to reach US$ 5,730.50 million by 2028.

Key Points: 
  • The global human papillomavirus (HPV) vaccine market was valued at US$ 4,273.84 million in 2022 and is projected to reach US$ 5,730.50 million by 2028.
  • Based on type, the human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine.
  • The global human papillomavirus (HPV) vaccine market, based on age, is segmented into 9 to 14 years and 15 to 45 years.
  • In terms of application, the global human papillomavirus (HPV) vaccine market is segmented into HPV-attributable cancers and genital warts.

Cervical Cancer Therapeutics Market Research Report 2022: Epidemiology & Pipeline Analysis 2022-2027 - 282+ Trials in Various Phases of Development - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 26, 2022

The "Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The cervical cancer portfolio contains a total of 169+ assets that are in various phases of development.
  • Based on the efficacy demonstrated with pembrolizumab and the significant role of PD-L1 in cervical cancer, various anti-P.D.-(L)1 agents are currently under investigation as first-line therapies in cervical cancer.
  • The cervical cancer treatment market is dominated by many companies offering generic drugs and particular pharma/biotech companies offering patented/commercial drugs for treating cervical cancer.

Nominations Open for 10th Annual International Harrington Prize for Innovation in Medicine

Retrieved on: 
Monday, July 25, 2022

CLEVELAND, July 25, 2022 /PRNewswire/ -- National and international nominations are being sought for the 2023 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application. 

Key Points: 
  • CLEVELAND, July 25, 2022 /PRNewswire/ --National and international nominations are being sought for the 2023 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application.
  • The Harrington Prize, which carries a $20,000 honorarium, is a collaboration between Harrington Discovery Institute at University Hospitals in Cleveland, Ohio and the American Society for Clinical Investigation (ASCI), one of the nation's oldest and most respected medical honor societies.
  • Harrington Discovery Institute is a nonprofit institute dedicated to helping physician-scientists accelerate promising discoveries into medicines for unmet needs.
  • A committee composed of members of the Harrington Discovery Institute Scientific Advisory Board and the ASCI Council will review the nominations and select the awardee.

Global Cancer Vaccine Market & Clinical Trials Outlook 2028: HPV Vaccine Sales Fueling Growth With Other Investigational Vaccines in Late Stage Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 21, 2022

The "Global Cancer Vaccine Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Vaccine Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • The significant increase in the growth of the market is mainly attributed to encouraging sales of HPV cancer vaccines and rising awareness among individuals regarding the benefits of HPV vaccination.
  • Apart from this, several investigational cancer vaccines have progressed towards late-stage clinical trials and are expected to gain market authorization, which will also have a positive impact on the growth of market.
  • Cancer Vaccines Trials Insight By Company, Country, and Indication
    To date, both therapeutic, as well as preventive cancer vaccines, have gained entry into the global market.

SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation

Retrieved on: 
Tuesday, July 12, 2022

Published in ESMOs Immuno-Oncology and Technology (IOTECH) journal, the review further explores the advantages of the companys Cell Squeeze technology in cell engineering and manufacturing as well as potential opportunities to develop additional clinical candidates with enhanced capabilities.

Key Points: 
  • Published in ESMOs Immuno-Oncology and Technology (IOTECH) journal, the review further explores the advantages of the companys Cell Squeeze technology in cell engineering and manufacturing as well as potential opportunities to develop additional clinical candidates with enhanced capabilities.
  • We look forward to potentially building on these early results through combination with various immunomodulatory drugs, such as checkpoint inhibitors.
  • SQZ has three ongoing Phase 1/2 clinical trials aiming to drive CD8 T cell responses against HPV16+ solid tumors.
  • SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases.

OmniPathology Announces the Launch of its Oropharyngeal HPV PCR Test

Retrieved on: 
Tuesday, July 12, 2022

The Oral HPV Test is a lab-developed test (LDT) performed on a Roche cobas 6800 and 8800 high-throughput platforms.

Key Points: 
  • The Oral HPV Test is a lab-developed test (LDT) performed on a Roche cobas 6800 and 8800 high-throughput platforms.
  • The Oral HPV Test detects 14 high-risk strains of HPV.
  • Launching this oropharyngeal HPV test is an exciting milestone for OmniPathology, especially since this is an underserved area for diagnostic testing.
  • For more information about the new Oral HPV Test, please contact OmniPathology at http://omnipathology.com/closer-look .

Europe Cervical Cancer Screening Market Report 2022: Sector Expected to be Valued at US$ 10.7 Billion in 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022

Europe Cervical Cancer Screening Market is expected to be valued at US$ 10.7 Billion in 2027.

Key Points: 
  • Europe Cervical Cancer Screening Market is expected to be valued at US$ 10.7 Billion in 2027.
  • As a result, cervical cancer screening is an essential aspect of a woman's routine health and can aid in cervical cancer prevention.
  • Europe Cervical Cancer Screening Market is estimated to expand with a CAGR of 3.3% during 2021-2027:
    The European Cervical Cancer Screening Market has grown in recent years due to an increase in the number of patients diagnosed with cervical cancer and increased awareness about cervical cancer screening programs.
  • By Country - Europe Cervical Cancer Test Market & Population Share Analysis:
    The Europe Cervical Cancer Test Market & Population Share Analysis has been done for the United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, and the Netherlands in our report.